Vita-Cos-Med Klett-Loch GmbH
Dermatological hair- & skincare with biologically active thymic peptide agents
The Vita-Cos-Med Klett-Loch GmbH is since more than 30 years successful engaged in research, development and distribution of dermatological hair- & skin-care with biologically active thymic peptide agents. The patented thymic peptide library GKL-02 is a mimicry of the natural thymic total extract and worldwide unique.
Thymic therapies are used successful in medical practice since decades. Now, the active ingredient GKL-02 allows the application of thymic therapies – without the use of ingredients of animal origin.
In-company research in the pharmaceutical and cosmetic field started in 1976, and in 1981 the company was able to demonstrate the unique effectiveness of the low molecular thymus hydrolysate GKL-01 in treating androgenetic hair loss.
Since then the brand Thymuskin is regarded as one of the leading preparations worldwide for counteracting hair loss and encouraging the formation of new hair. Further pharmaceutical innovations such as the development of the bovine-free low molecular, statistical thymic peptide library GKL-02 and numerous other pharmaceutical patents and products have followed.
In 2005 Thymuskin SCLERO discret was introduced, for the treatment of the skin of the intimate area, escpecially to treat Lichen sclerosus. During a clinical observational study, an improvement up to complete freedom of symptoms could be confirmed in 80% of all cases (M. Loehnert, S. Rappich, M. Hagedorn: Treatment and care of lichen sclerosus, Sept. 2005). The preparation is also positively mentioned in the well noted Encyclopedia of Dermatology, Allergy, Environmental medicine, Altmeyer & Paech 2010: "Analog good results, compared to the calcineurin inhibitors, were made with the approach using a thymic peptide active agent".
Another major success was the introduction of Thymrevit Revitalizing Capsules in 2008. This dietary supplement for special medical purposes has helped many people since in the treatment of diseases associated with immune disorders and immune weakness. Right from the beginning we have supported the technology transfer of biochemical innovations in close cooperation with universities and teaching hospitals.